Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kina

Indication
Non Small Cell Lung Cancer

Other upcoming events for NUVB

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i
Patent ExpiryPatent/Exclusivity Expiry: IBTROZI
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kina — NUVB Phase 3 Readout | BioSniper